Skip to content

Contact +44 (0) 20 7060 7474 email us

Healthcare

Atrial Fibrillation

Drug Pipeline Analysis and Market Forecasts to 2016

Publication Date February 2010
Publisher Globaldata
Product Type Report
Pages 47
ISBN Number not applicable
Product Code GDA00156

Price

£1,320.00
approximately: $1,999 | €1,473

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

GlobalData, the industry analysis specialist's new report, Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global atrial fibrillation therapeutics market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global atrial fibrillation market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides a valuable insight into the pipeline products within the global atrial fibrillation therapeutics sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

  • Annualized global atrial fibrillation therapeutics market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
  • Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
  • Pipeline analysis data providing an overview of different phases, mechanisms of action being developed, and emerging trends. Key classes of mechanism of action include Factor Xa Inhibitors, direct thrombin inhibitors,A1 adenosine receptor agonists, multiple and selective ion channel blockers and gap junction inhibitors.
  • Analysis of the current and future market competition in the global atrial fibrillation therapeutics market. Key market players covered are Bayer Healthcare, Proctor and Gamble, Boehringer Ingelheim, Sanofi Aventis, Cardiome Pharma Corp and Astellas Pharma US and Xention Ltd.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and the implications for the future market associated with atrial fibrillation.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global atrial fibrillation therapeutics market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments, and companies likely to impact the global atrial fibrillation therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
  • What's the next big thing in the global atrial fibrillation market landscape? Identify, understand, and capitalize.

Contents

  • 1 Table of contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Atrial Fibrillation: Market Characterization
    • 2.1 Overview
    • 2.2 Atrial Fibrillation Market Size
    • 2.3 Atrial Fibrillation Market Forecast and CAGR
    • 2.4 Drivers and Barriers for the Atrial Fibrillation Market
      • 2.4.1 Drivers of the Atrial Fibrillation Market
      • 2.4.2 Barriers for the Atrial Fibrillation Market
    • 2.5 Opportunity and Unmet Need
    • 2.6 Key Takeaway
  • 3 Atrial Fibrillation Market: Competitive Assessment
    • 3.1 Overview
    • 3.2 Strategic Competitor Assessment
    • 3.3 Product Profile for the Major Marketed Products in the Atrial Fibrillation Market
      • 3.3.1 Multaq
      • 3.3.2 Tikosyn
      • 3.3.3 Tambocor
      • 3.3.4 Coumadin (Warfarin- Anticoagulants)
      • 3.3.5 Betapace AF
    • 3.4 Key Takeaway
  • 4 Atrial Fibrillation: Pipeline Assessment
    • 4.1 Overview
    • 4.2 Strategic Pipeline Assessment
      • 4.2.1 Technology Trends Analytic Framework
    • 4.3 Atrial Fibrillation Therapeutics - Promising Drugs under Clinical Development
    • 4.4 Drugs under Clinical Development
      • 4.4.1 Xarelto
      • 4.4.2 Pradaxa
      • 4.4.3 Stedicor
      • 4.4.4 Kynapid
      • 4.4.5 Edoxaban
    • 4.5 Atrial Fibrillation Therapeutics Market - Clinical Pipeline by Mechanism of Action
    • 4.6 Atrial Fibrillation Pipeline - Pipeline by Clinical Phases of Development
      • 4.6.1 Atrial Fibrillation Therapeutics - Phase III Clinical Pipeline
      • 4.6.2 Atrial Fibrillation Therapeutics - Phase II Clinical Pipeline
      • 4.6.3 Atrial Fibrillation Therapeutics - Phase I Clinical Pipeline
      • 4.6.4 Atrial Fibrillation Therapeutics - Preclinical Pipeline
    • 4.7 Discontinued / Suspended Drugs for Atrial Fibrillation
    • 4.8 Key Takeaway
  • 5 Atrial Fibrillation Market: Implications for Future Market Competition
  • 6 Atrial Fibrillation Market: Future Players in the Atrial Fibrillation Market
    • 6.1 Introduction
    • 6.2 Cardiome Pharma Corp and Astellas Pharma US, Inc
      • 6.2.1 Overview
      • 6.2.2 Business Description
      • 6.2.3 CV Portfolio
      • 6.2.4 Atrial Fibrillation Product Portfolio
    • 6.3 Sanofi Aventis
      • 6.3.1 Overview
      • 6.3.2 Business Description
      • 6.3.3 CV Portfolio
    • 6.4 Daiichi Sankyo Company, Limited
      • 6.4.1 Overview
      • 6.4.2 Business Description
      • 6.4.3 CV Portfolio
      • 6.4.4 Atrial Fibrillation product portfolio
    • 6.5 Boehringer Ingelheim
      • 6.5.1 Overview
      • 6.5.2 Business Description
      • 6.5.3 CV Portfolio
      • 6.5.4 Atrial Fibrillation Product Portfolio
    • 6.6 Procter and Gamble
      • 6.6.1 Overview
      • 6.6.2 Business Description
      • 6.6.3 CV Portfolio
      • 6.6.4 Atrial Fibrillation Product Portfolio
    • 6.7 Bayer Healthcare
      • 6.7.1 Overview
      • 6.7.2 Business Description
      • 6.7.3 CV Portfolio
      • 6.7.4 Atrial Fibrillation Product Portfolio
  • 7 Atrial Fibrillation Market: Appendix
    • 7.1 Definitions
    • 7.2 Acronyms
    • 7.3 Research Methodology
      • 7.3.1 Coverage
      • 7.3.2 Secondary Research
      • 7.3.3 Forecasting
      • 7.3.4 Primary Research
      • 7.3.5 Expert Panels
    • 7.4 Contact Us
    • 7.5 Disclaimer
    • 7.6 Sources
  • List of Tables
    • Table 1: Global Atrial Fibrillation Market Revenues, 2001-2009
    • Table 2: Global Atrial Fibrillation Market Forecast, 2009-2016
    • Table 3: Strategic Competitor Assessment of the Major Marketed Products in Atrial Fibrillation, 2010
    • Table 4: A summary of Key Phase III clinical trials for Multaq
    • Table 5: Major Marketed Products in the Atrial Fibrillation Market, 2010
    • Table 6: Atrial Fibrillation Therapeutics -Promising Drugs Under Clinical Development, 2010
    • Table 7: Clinical study details on ROCKET-AF with Xarelto
    • Table 8: Atrial Fibrillation Therapeutics - Phase III Clinical Pipeline, 2010
    • Table 9: Atrial Fibrillation Therapeutics - Phase II Clinical Pipeline, 2010
    • Table 10: Atrial Fibrillation Therapeutics - Phase I Clinical Pipeline, 2010
    • Table 11: Atrial Fibrillation Therapeutics - Preclinical Pipeline, 2010
    • Table 12: List of Discontinued Drugs for Atrial Fibrillation, 2010
    • Table 13: Cardiome and Astellas Pharma Inc. - CV and Atrial Fibrillation Pipeline, 2010
    • Table 14: Sanofi-Aventis - CV and Atrial Fibrillation Pipeline, 2010
    • Table 15: Daiichi Sankyo Co. Ltd - CV and Atrial Fibrillation Pipeline, 2010
    • Table 16: Boehringer Ingelheim - Atrial Fibrillation Pipeline, 2010
    • Table 17: P&G - Atrial Fibrillation Pipeline Products, 2010
    • Table 18: Bayer HealthCare - CV and Atrial Fibrillation Pipeline, 2010
    • Table 19: Clinical study details on ROCKET-AF with Xarelto
  • List of Figures
    • Figure 1: Global Atrial Fibrillation Market Revenues, 2001-2009
    • Figure 2: Global Atrial Fibrillation Market Forecast, 2009-2016
    • Figure 3: Opportunity and Unmet Need in the Atrial Fibrillation Market, 2010
    • Figure 4: Technology Trends Analytic Framework of the Atrial Fibrillation Pipeline, 2010
    • Figure 5: Technology Trends Analytic Framework of Atrial Fibrillation Pipeline - Description, 2010
    • Figure 6: Atrial Fibrillation Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2010
    • Figure 7: Atrial Fibrillation Pipeline by Phase of Clinical Development, 2010
    • Figure 8: Implications for Future Market Competition in the Atrial Fibrillation Market, 2010
    • Figure 9: Atrial Fibrillation Therapeutics Market - Clinical Pipeline by Company, 2010
    • Figure 10: GlobalData Methodology
    • Figure 11: GlobalData Market Forecasting Model